CN109601680A - A kind of maintenance joint and the Astaxanthin In Haematococcus Pluvialis pressed candy of connective tissue health and preparation method thereof - Google Patents
A kind of maintenance joint and the Astaxanthin In Haematococcus Pluvialis pressed candy of connective tissue health and preparation method thereof Download PDFInfo
- Publication number
- CN109601680A CN109601680A CN201910045882.6A CN201910045882A CN109601680A CN 109601680 A CN109601680 A CN 109601680A CN 201910045882 A CN201910045882 A CN 201910045882A CN 109601680 A CN109601680 A CN 109601680A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- vitamin
- joint
- pressed candy
- haematococcus pluvialis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 68
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 68
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 68
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 68
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 68
- 235000009508 confectionery Nutrition 0.000 title claims abstract description 45
- 241000168517 Haematococcus lacustris Species 0.000 title claims abstract description 30
- 230000036541 health Effects 0.000 title claims abstract description 24
- 210000002808 connective tissue Anatomy 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000012423 maintenance Methods 0.000 title description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 52
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 40
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 40
- 235000008434 ginseng Nutrition 0.000 claims abstract description 40
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims abstract description 28
- 235000020243 first infant milk formula Nutrition 0.000 claims abstract description 28
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 26
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 26
- 239000011718 vitamin C Substances 0.000 claims abstract description 26
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims abstract description 23
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 23
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 23
- 239000000905 isomalt Substances 0.000 claims abstract description 23
- 235000010439 isomalt Nutrition 0.000 claims abstract description 23
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 23
- 239000011710 vitamin D Substances 0.000 claims abstract description 23
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 23
- 229940046008 vitamin d Drugs 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 21
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 21
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 21
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 20
- 210000005067 joint tissue Anatomy 0.000 claims abstract description 18
- 241000208340 Araliaceae Species 0.000 claims abstract 7
- 239000000843 powder Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 239000004365 Protease Substances 0.000 claims description 16
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 16
- 235000013399 edible fruits Nutrition 0.000 claims description 16
- 239000004615 ingredient Substances 0.000 claims description 15
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 238000004806 packaging method and process Methods 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 108010004032 Bromelains Proteins 0.000 claims description 8
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 8
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 8
- 108090000526 Papain Proteins 0.000 claims description 8
- 235000019835 bromelain Nutrition 0.000 claims description 8
- 235000012754 curcumin Nutrition 0.000 claims description 8
- 239000004148 curcumin Substances 0.000 claims description 8
- 229940109262 curcumin Drugs 0.000 claims description 8
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 8
- 235000019834 papain Nutrition 0.000 claims description 8
- 229940055729 papain Drugs 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 229920001202 Inulin Polymers 0.000 claims description 6
- 102000004407 Lactalbumin Human genes 0.000 claims description 6
- 108090000942 Lactalbumin Proteins 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 6
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 6
- 235000021014 blueberries Nutrition 0.000 claims description 6
- 235000021323 fish oil Nutrition 0.000 claims description 6
- 229930182494 ginsenoside Natural products 0.000 claims description 6
- 229940089161 ginsenoside Drugs 0.000 claims description 6
- 229940029339 inulin Drugs 0.000 claims description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000004006 olive oil Substances 0.000 claims description 6
- 235000008390 olive oil Nutrition 0.000 claims description 6
- 235000019100 piperine Nutrition 0.000 claims description 6
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims description 6
- 229940075559 piperine Drugs 0.000 claims description 6
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims description 6
- 238000012372 quality testing Methods 0.000 claims description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 6
- 229930182490 saponin Natural products 0.000 claims description 6
- 150000007949 saponins Chemical class 0.000 claims description 6
- 235000020254 sheep milk Nutrition 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 6
- 241000168525 Haematococcus Species 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 4
- 210000003022 colostrum Anatomy 0.000 claims description 3
- 235000021277 colostrum Nutrition 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 12
- 235000013305 food Nutrition 0.000 abstract description 12
- 230000003078 antioxidant effect Effects 0.000 abstract description 11
- 239000003963 antioxidant agent Substances 0.000 abstract description 7
- 235000006708 antioxidants Nutrition 0.000 abstract description 7
- 235000016709 nutrition Nutrition 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 230000035764 nutrition Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000000295 complement effect Effects 0.000 abstract description 4
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 208000029549 Muscle injury Diseases 0.000 abstract description 3
- 208000000112 Myalgia Diseases 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 240000004371 Panax ginseng Species 0.000 description 33
- 208000002193 Pain Diseases 0.000 description 19
- 230000036407 pain Effects 0.000 description 19
- 239000000047 product Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 230000012010 growth Effects 0.000 description 9
- 206010003246 arthritis Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 208000012659 Joint disease Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 244000163122 Curcuma domestica Species 0.000 description 4
- 235000003392 Curcuma domestica Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000003373 curcuma longa Nutrition 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- -1 oxygen radical Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 235000013976 turmeric Nutrition 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001741 anti-phlogistic effect Effects 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 235000021196 dietary intervention Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 2
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 2
- 244000298715 Actinidia chinensis Species 0.000 description 2
- 235000009434 Actinidia chinensis Nutrition 0.000 description 2
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- 244000189799 Asimina triloba Species 0.000 description 2
- 235000006264 Asimina triloba Nutrition 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 235000009467 Carica papaya Nutrition 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 206010060820 Joint injury Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 244000077233 Vaccinium uliginosum Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229930014669 anthocyanidin Natural products 0.000 description 2
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 2
- 235000008758 anthocyanidins Nutrition 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 102000005525 fibrillarin Human genes 0.000 description 2
- 108020002231 fibrillarin Proteins 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 230000006450 immune cell response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940118199 levulan Drugs 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241001421185 Anomis Species 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 206010072970 Meniscus injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001749 antrachitic effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000005528 popliteal cyst Diseases 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/40—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the fats used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/44—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/46—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing dairy products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a kind of Astaxanthin In Haematococcus Pluvialis pressed candy for safeguarding joint and connective tissue health, the raw materials including following mass percentage content: astaxanthin 15~30%, isomalt 5~20%, first milk basic protein 10~20%, ginseng 0.5~2%, microcrystalline cellulose 30~47%, vitamin D 0.5~1% and vitamin C 0.5~1%.Antioxidant astaxanthin and people are participated in isomalt, first milk basic protein, microcrystalline cellulose, vitamin D and vitamin C and combined according to a certain percentage by the present invention, play its complementary and synergistic effect, antioxidant effect is preferable, interior free yl can be removed, anti-inflammatory, anti-inflammatory, raising joint flexibility ratio, and aerobic metabolism can be strengthened, myalgia is reduced, endurance is improved；Muscle damage is reduced, recovery time is shortened；Have the advantages that product is in good taste, quality is stable, full of nutrition, food therapy effect is significant, easy to carry, preparation method is simple, is easy to the factorial production.
Description
Technical field
The invention belongs to technical field of food production, and in particular to a kind of rain life for safeguarding joint and connective tissue health is red
Ball algae astaxanthin pressed candy and preparation method thereof.
Background technique
10% of China's Human Osteoarthritis more than population, up to 100,000,000 or more, and disease incidence increases with the age and is increased
Add.The incidence trend of orthopaedic disease allows of no optimist, and it is 45% that gonitis disease incidence, which increases, between 20 years 1990~2010 years, disables
Rate ranks the second in the world, and accounts for 21.3%；According to reckoning, the medical expense generated to the slow disease of the year two thousand twenty China orthopaedics will increase to 850
Hundred million；It will be up to 1,800,000,000,000 to the year two thousand fifty.Joint disease clinical manifestation be swelling, pain, stiff, hyperplasia, patient's freedom of action by
Limit even causes deformity, also can be involved articulations digitorum manus, hip joint etc., seriously affects quality of life and the service life of the mankind.Endanger the mankind
Joint prob mainly have Osteoarthritis, rheumatoid arthritis, urarthritis and osteoporosis etc..As whole body
The most frequent knee joint of activity is the highest joint of whole body disease incidence, and normal person will appear cartilaginous tissue by 30 years old later
, there is different degrees of joint prob, is mainly shown as pain, swelling, tenderness, limitation of activity, activity in middle nutriment decline
When have fricative, sometimes even twist lock.Common diseases of knee joint has knee joint osseous arthritis, meniscus injury, kneecap soft
Change disease, prepatellar bursitis, synovitis, osteoproliferation He popliteal cyst etc..Above-mentioned disease is mainly since cartilage metabolism is abnormal, soft
Bone tissue is to caused by joint protection missing.
Haematococcus pluvialis is the highest biology of natural astaxanthin content, and on other occasions, haematococcus pluvialis can accumulate
The tired astaxanthin for accounting for its 1% or more dry weight, and astaxanthin structure required for the mechanism of institute's astaxanthin-containing and cultivation object first is that,
It is acknowledged as the best biological source of natural astaxanthin.A kind of fat soluble carotenoids, have inoxidizability, it is antitumor and
The many important physiology and biological function such as strengthen immunity, inoxidizability are 500~1000 times of vitamin E, for recklessly
10 times of radish element, are the powerful antioxidants generally acknowledged in hydrobiontic alga, can inhibit senile plaque in human body by anti-oxidant
It is formed, fatigue tool is inspected to video display terminal operator and is improved significantly, additionally aids what elimination was generated by the time difference
Physical discomfort, effect are also more obvious than common epiphysin.So astaxanthin has important nutritive value and dietotherapy
Effect
Joint disease mainly has following therapeutic modality: drug therapy, operative treatment and nutritional intervention etc. at present.Drug therapy and hand
Art treatment arc leaves sequelae to human health, and nutritional intervention is primarily referred to as using joint dietary supplements, joint meal supplement
Agent etc. adjusts the balance of cartilaginous tissue anabolism and catabolism, adjusts immune response, redox reaction and elimination
Free radical etc. provides good condition for synovial fluid and cartilage cell's external environment.More using nutritional intervention bone and joint diseases benefit,
Small side effects, expense are low, are of great significance to the prevention and management of bone and joint diseases.Although currently on the market for joint disease
The health care product and food that disease prevents and treats are more, still, prevent and treat the food of joint disease using astaxanthin in the market
Product are less, are substantially using the theory of Chinese traditional treatment and prepare, to a certain extent can relieve pain, but effect
Ingredient and healthcare function relevance are poor, and all ideal requirement is not achieved in nutritional ingredient and treatment curative effect.Therefore, it develops
A kind of formula is reasonable, carry convenient, significant in efficacy, full of nutrition, anti-inflammatory, antiphlogistic effects are good and safe without toxic side effect
Maintenance joint and the Astaxanthin In Haematococcus Pluvialis pressed candy of connective tissue health and preparation method thereof be that pipe needs.
Summary of the invention
In order to solve the problems, such as background technique, the purpose of the present invention is to provide a kind of formulas rationally, carries food
With convenient, significant in efficacy, full of nutrition, anti-inflammatory, antiphlogistic effects are good and maintenance joint and the connective tissue of safe without toxic side effect
The Astaxanthin In Haematococcus Pluvialis pressed candy and preparation method thereof of health.
The Astaxanthin In Haematococcus Pluvialis pressed candy in maintenance joint and connective tissue health of the present invention, including it is following
The raw material of mass percentage content: astaxanthin 15~30%, isomalt 5~20%, first milk basic protein 10~20%, people
Join (artificial growth) 0.5~2%, microcrystalline cellulose 30~47%, vitamin D 0.5~1% and vitamin C 0.5~1%.
Further, further include in the raw material 0.5~1% auxiliary material, it is preferable that the auxiliary material includes following parts by weight
Ingredient: 1~20 part of inulin, 1~10 part of seabuckthorn fruit powder and 1~10 part of blueberry dry powder.
It further, further include 0.01~0.05% anti-inflammatory agent and 0.01~0.05% antioncotic in the raw material.Preferably,
The anti-inflammatory agent includes one of and two or more mixture in fish oil, olive oil, curcumin and piperine；The detumescence
Agent includes one of which or two kinds of mixture in bromelain and papain.
Further, the ginseng is the one of which in ginseng stem and leave general saponin, ginsenoside and ginseng pulverate.
Further, the just milkiness albumen includes the ingredient of following weight backup ratio: sheep milk powder 20~40%, milk powder
20~40%, collagen protein powder 10~30%, α-lactalbumin 1~5%, first milk basic protein 1~5%, 0.5~2% and of magnesium stearate
Se-enriched yeast 1~5%.
Further, the astaxanthin is haematococcus pluvialis extract.
The preparation method of Astaxanthin In Haematococcus Pluvialis pressed candy of the present invention the following steps are included:
1. stock: weighing the following raw material: astaxanthin 15~30%, isomalt 5~20%, colostrum alkali by mass percentage
Property protein 10~20%, ginseng 0.5~2%, microcrystalline cellulose 30~47%, vitamin D 0.5~1% and vitamin C 0.5~1%；
2. mixing: by astaxanthin, isomalt, first milk basic protein, ginseng, microcrystalline cellulose, vitamin D and vitamin C
It is placed in batch mixer, 20~30min is mixed under the revolving speed of 1000~1500r/min and obtains mixture；
3. sterilizing: mixture is placed in sterilizer, 100~120 DEG C at a temperature of sterilize 5~6s；
4. tabletting: by the mixture input tablet press machine after sterilizing, tabletting is carried out under the pressure of 50~100KN, obtains tabletting
Candy；
5. packaging: the pressed candy after tabletting is subjected to quality testing, and carries out disinfection by ultraviolet light, packaging, can be prepared by finished product,
The quality of pressed candy is 0.5 ± 0.01g.
Ingredient and the mechanism of action are as follows the effect of each raw material in the present invention:
Astaxanthin: astaxanthin is the highest level product of a kind of fat soluble carotenoids and carotenogenesis, in deep
Pink, chemical structure are similar to beta carotene.Astaxanthin is one of strongest natural in the world, can be effectively clear
Except intracellular oxygen radical, enhance cytothesis ability, maintain organism balance and reduce the accumulation of senile cell, from inside to outside
Cell and DNA health are protected, to protect skin health, promotes hair growth, anti-aging alleviates sports fatigue, invigorates.
Domestic and international numerous studies confirm that astaxanthin has stronger antioxidant activity, are improving immunity, pre- preventing tumor, cardiovascular disease
The occurrence and development of the chronic diseases such as disease, diabetes, delay senescence etc. have positive facilitation.
Isomalt: isomalt is a kind of functional Sugar Alcohol, is the excellent of sucrose, starch sugar and other sugar alcohols
Good substitute, sugariness are the 50~60% of sucrose, have agent of low hygroscopicity, high stability, height endurability, low in calories, sweet pure
Advantage.
First milk basic protein: first milk basic protein is approved for new resource food in 2009, have the function of following features and:
Activated protein, molecular weight is small, can be done directly on bone cells, promotes bone metabolism, can coordinate osteoblast and break
The activity of osteocyte keeps the dynamic equilibrium of the two, promotes bone growth.
Ginseng: ginseng reinforces vital energy, and reinforces the spleen to benefit the lung, and promotes the production of body fluid to quench thirst, tranquilize the mind and promote the intelligence, main tonifying five zang organs, soothe the nerves, determine soul,
Stop palpitate with fear removes pathogenic factor, improving eyesight, happy, intelligence development, and long term usage, which is made light of one's life by commiting suicide, is healthy and strong；It is that the panacea of tonifying Qi can enter the vital organs of the human body；Control all void
Disease is reinforced vital energy, prevent prolapse and engender liquid, cures mainly amnesia dizziness and headache impotence and premature ejaculation urine urgency-frequency.The present invention uses ginseng for by existing
Standard criterion artificial growth simultaneously detects qualified ginseng.
Microcrystalline cellulose: microcrystalline cellulose has both dietary fiber and stabilizer function, at the same also have promote intestines peristalsis,
The effect of improvement intestinal flora ecological balance, preventing hypertension, hyperlipidemia, more active constituents can be carried, and to small
Intestinal mucosa plays a protective role, and is conducive to the absorbability for improving enteron aisle.
Vitamin D: vitamin D is sterol analog derivative, has anti-rachitic effect.
Vitamin C: also known as L-AA, is nutrient needed by human.
In summary: the present invention eliminates the free radical of human body using the anti-oxidation function of astaxanthin, utilizes isomaltoketose
The problems such as alcohol, first milk basic protein and life slow down joint injury, qi depression to blood stasis, while supplementing energy and nutrition, reasonably
Collocation microcrystalline cellulose, vitamin D and vitamin C can be improved the immunity of human body itself, improve blood admonitory talk to subordinates, it is fine to repair flesh
Dimension.
It is analyzed from above-mentioned primary raw material and trophic function, antioxidant astaxanthin and people are participated in different malt ketone by the present invention
Sugar alcohol, first milk basic protein microcrystalline cellulose, vitamin D and vitamin C combine according to a certain percentage, play its complementary and collaboration
Effect, antioxidant effect is preferable, can remove interior free yl, anti-inflammatory, anti-inflammatory, improves joint flexibility ratio, keeps action more suitable
Freely, and aerobic metabolism can be strengthened, reduces myalgia, improves endurance；Muscle damage is reduced, recovery time is shortened；Promote fat
Burning obtains higher energy grade；Function of joint, enhancing immunity of organisms after can also maintaining strenuous exercise, not only have and produce
Product are in good taste, quality is stable, full of nutrition, food therapy effect is significant, easy to carry, preparation method is simple, are easy to the factorial production
The advantages of, and the food products market of Astaxanthin In Haematococcus Pluvialis is further enriched, it is very suitable to arthritic or alleviation
The crowd of tiring exercises drinks, and has preferable utilization and extention value.
Specific embodiment
Below with reference to embodiment, the present invention is further illustrated, but the present invention is limited in any way,
Based on present invention teach that it is made it is any transform or replace, all belong to the scope of protection of the present invention.
Embodiment 1:
The Astaxanthin In Haematococcus Pluvialis pressed candy in maintenance joint and connective tissue health described in the present embodiment 1, including with
The raw material of lower mass percentage content: astaxanthin 15%, isomalt 20, first milk basic protein 20%, ginseng 2%, crystallite
Cellulose 41%, vitamine D1 % and vitamin C 1%.The present invention uses ginseng by current standard specifications artificial growth and to detect conjunction
The ginseng of lattice.
In the present embodiment: the ginseng is the one of which in ginseng stem and leave general saponin, ginsenoside and ginseng pulverate.
The just milkiness albumen includes the ingredient of following weight backup ratio: sheep milk powder 20%, milk powder 40%, collagen protein powder
23%, α-lactalbumin 5%, first milk basic protein 5%, magnesium stearate 2% and Se-enriched yeast 5%.
The astaxanthin is haematococcus pluvialis extract.
The preparation method of the raw haematococcus astaxanthin pressed candy the following steps are included:
1. stock: weighing the following raw material: astaxanthin 15%, isomalt 20, first milk basic protein by mass percentage
20%, ginseng 2%, microcrystalline cellulose 41%, vitamine D1 % and vitamin C 1%；
2. mixing: by astaxanthin, isomalt, first milk basic protein, ginseng, microcrystalline cellulose, vitamin D and vitamin C
It is placed in batch mixer, 20min is mixed under the revolving speed of 1000r/min and obtains mixture；
3. sterilizing: mixture is placed in sterilizer, 100 DEG C at a temperature of sterilize 5s；
4. tabletting: by the mixture input tablet press machine after sterilizing, tabletting is carried out under the pressure of 50KN, obtains pressed candy；
5. packaging: the pressed candy after tabletting is subjected to quality testing, and carries out disinfection by ultraviolet light, packaging, can be prepared by finished product,
The quality of pressed candy is 0.5g.
Embodiment 2
The Astaxanthin In Haematococcus Pluvialis pressed candy in joint and connective tissue health is safeguarded described in the present embodiment 2, including following
The raw material of mass percentage content: astaxanthin 28%, isomalt 5%, first milk basic protein 20%, people 1.5%, crystallite are fine
Dimension element 43.5%, vitamin D 0.5%, vitamin C 1% and auxiliary material 0.5%.
In this embodiment:
The auxiliary material includes the ingredient of following parts by weight: 1 part of inulin, 10 parts of seabuckthorn fruit powder and 10 parts of blueberry dry powder.
Inulin also known as synanthrin are the mixtures of a kind of natural levulan, by many state approvals in the world as food
Savor nutritional supplement.As a kind of natural soluble dietary fiber, into human body after not by stomach and small intestinal absorption and directly into
Enter big enteral, promotes preferentially to be utilized by probiotics such as Bifidobacterium, lactic acid bacterias while intestines peristalsis, be conducive to the increasing of probiotics
Value；Growth of probiotics reduces gut pH, inhibits the growth of harmful bacteria, to be conducive to intestinal health.
Rich in biological active matters such as a large amount of vitamin C, vitamin E, bata-carotene, flavones, SOD in seabuckthorn fruit powder reality
The various amino acid and microelement of matter and needed by human body, Vc content are 2~5 times of Kiwi berry, referred to as " king of fruit ",
Therefore sea-buckthorn has the effects that improve immunity, brain tonic and intelligence development, lowering blood pressure and blood fat.
Blueberry dry powder anthocyanidin rich in is a kind of effective natural of removing people's interior free yl, it is enough
The decomposition and exclusion for improving blood circulation, protection eyesight, eliminating oedema, moisturizing the skin, accelerate harmful cholesterol, protection
Heart mitigates allergy inflammation, improvement vein, enhancing memory, delaying senility and the risk for reducing apoplexy, improves anoxic, delays
Solve premenstrual syndrome.
After above-mentioned auxiliary material and various raw materials cooperate according to a certain percentage, its complementary and synergistic effect is played, is reinforced anti-oxidant
Effect, promote the metabolism of bone, promote the reparation of cartilage.
The ginseng is the one of which in ginseng stem and leave general saponin, ginsenoside and ginseng pulverate.
The just milkiness albumen includes the ingredient of following weight backup ratio: sheep milk powder 30%, milk powder 30%, collagen protein powder
30%, α-lactalbumin 2%, first milk basic protein 2%, magnesium stearate 2% and Se-enriched yeast 4%.
The astaxanthin is haematococcus pluvialis extract.
The preparation method of the life haematococcus astaxanthin pressed candy the following steps are included:
1. stock: weighing the following raw material: shrimp astaxanthin 28%, isomalt 5%, first milk basic protein by mass percentage
20%, people 1.5%, microcrystalline cellulose 43.5%, vitamin D 0.5%, vitamin C 1% and auxiliary material 0.5%；
2. mixing: by astaxanthin, isomalt, first milk basic protein, ginseng, microcrystalline cellulose, vitamin D, vitamin C and
Auxiliary material is placed in batch mixer, and 25min is mixed under the revolving speed of 1200r/min and obtains mixture；
3. sterilizing: mixture is placed in sterilizer, 110 DEG C at a temperature of sterilize 6s；
4. tabletting: by the mixture input tablet press machine after sterilizing, tabletting is carried out under the pressure of 80KN, obtains pressed candy；
5. packaging: the pressed candy after tabletting is subjected to quality testing, and carries out disinfection by ultraviolet light, packaging, can be prepared by finished product,
The quality of pressed candy is 0.51g.
Embodiment 3
The Astaxanthin In Haematococcus Pluvialis pressed candy in joint and connective tissue health is safeguarded described in the present embodiment 3, including following
The raw material of mass percentage content: astaxanthin 30%, isomalt 20%, first milk basic protein 10%, ginseng 2%, crystallite are fine
Dimension element 35%, vitamin D 1%, vitamin C 0.99%, auxiliary material 0.99%, anti-inflammatory agent 0.01% and antioncotic 0.01%.
In the present embodiment
The auxiliary material includes the ingredient of following parts by weight: 20 parts of inulin, 1 part of seabuckthorn fruit powder and 1 part of blueberry dry powder.
Inulin also known as synanthrin are the mixtures of a kind of natural levulan, by many state approvals in the world as food
Savor nutritional supplement.As a kind of natural soluble dietary fiber, into human body after not by stomach and small intestinal absorption and directly into
Enter big enteral, promotes preferentially to be utilized by probiotics such as Bifidobacterium, lactic acid bacterias while intestines peristalsis, be conducive to the increasing of probiotics
Value；Growth of probiotics reduces gut pH, inhibits the growth of harmful bacteria, to be conducive to intestinal health.
Rich in biological active matters such as a large amount of vitamin C, vitamin E, bata-carotene, flavones, SOD in seabuckthorn fruit powder reality
The various amino acid and microelement of matter and needed by human body, Vc content are 2~5 times of Kiwi berry, referred to as " king of fruit ",
Therefore sea-buckthorn has the effects that improve immunity, brain tonic and intelligence development, lowering blood pressure and blood fat
Blueberry dry powder anthocyanidin rich in is a kind of effective natural of removing people's interior free yl, it is enough to improve
Blood circulation, the decomposition and exclusion protection eyesight, eliminated oedema, moisturize the skin, accelerate harmful cholesterol, cardioprotection,
Mitigate allergy inflammation, improve vein, enhancing memory, delaying senility and the risk for reducing apoplexy, improves anoxic, alleviates warp
Preceding syndrome.
The anti-inflammatory agent includes one of and two or more mixture in fish oil, olive oil, curcumin and piperine；
The antioncotic includes one of which or two kinds of mixture in bromelain and papain.
Fish oil, olive oil are rich in unsaturated fatty acid, and the absorption, osteoclast synthesis, prostaglandin by adjusting calcium are closed
The growth metabolism that bone is influenced at equal inhibits arthritis reaction, relieves pain.
Turmeric is turmeric zingiberaceous plant, and main active is curcumin, and curcumin has anti-infective, anti-oxidant and anti-
Inflammation effect etc..
Piperine by inhibiting the expression of the inflammatory factors such as Serum TNF-α, IL-1 β, IL-6 during arthritis, thus
Play the role of inhibiting osteoarthritis.
Bromelain and papain are extracted from pineapple and pawpaw respectively to be obtained, and bromelain has anti-inflammatory,
Inhibit immune cell responses, promotes the effect of absorption of nutrient ingredients；Papain has extremely strong capacity of decomposition, can promote fibre
The hydrolysis of fibrillarin eliminates the fibrin as caused by the reasons such as inflammation or wound, makes inflammatory resolution, plays anti-inflammatory, elimination
The effect of oedema.
A certain proportion of auxiliary material, anti-inflammatory agent and antioncotic is added on the basis of having raw material in the present embodiment, between several substances
After interaction, from articular cartilage reparation, the blocking of inflammatory signals access and improve body fluid local circulation eliminate oedema these
Aspect synergistic effect, effectively maintenance articulation health.
The ginseng is the one of which in ginseng stem and leave general saponin, ginsenoside and ginseng pulverate.
The just milkiness albumen includes the ingredient of following weight backup ratio: sheep milk powder 35%, milk powder 25%, collagen protein powder
25%, α-lactalbumin 5%, first milk basic protein 5%, magnesium stearate 2% and Se-enriched yeast 3%.
The astaxanthin is haematococcus pluvialis extract.
The preparation method of the life haematococcus astaxanthin pressed candy the following steps are included:
1. stock: weighing the following raw material: astaxanthin 30%, isomalt 20%, first milk basic protein by mass percentage
10%, ginseng 2%, microcrystalline cellulose 35%, vitamin D 1%, vitamin C 0.99%, auxiliary material 0.99%, anti-inflammatory agent 0.01% and detumescence
Agent 0.01%；
2. mixing: by astaxanthin, isomalt, first milk basic protein, ginseng, microcrystalline cellulose, vitamin D, vitamin C,
Auxiliary material, anti-inflammatory agent and antioncotic are placed in batch mixer, and 30min is mixed under the revolving speed of 1800r/min and obtains mixture；
3. sterilizing: mixture is placed in sterilizer, 115 DEG C at a temperature of sterilize 5s；
4. tabletting: by the mixture input tablet press machine after sterilizing, tabletting is carried out under the pressure of 90KN, obtains pressed candy；
5. packaging: the pressed candy after tabletting is subjected to quality testing, and carries out disinfection by ultraviolet light, packaging, can be prepared by finished product,
The quality of pressed candy is 0.49g.
Embodiment 4
The Astaxanthin In Haematococcus Pluvialis pressed candy in joint and connective tissue health is safeguarded described in the present embodiment 4, including following
The raw material of mass percentage content: astaxanthin 19.5%, isomalt 20%, first milk basic protein 10%, ginseng 1.5%, micro-
Crystalline cellulose 47%, vitamin D 0.95% and vitamin C 0.95%, anti-inflammatory agent 0.05% and antioncotic 0.05%.
In this embodiment:
The anti-inflammatory agent includes one of and two or more mixture in fish oil, olive oil, curcumin and piperine；It is described
Antioncotic includes one of which or two kinds of mixture in bromelain and papain.
Fish oil, olive oil are rich in unsaturated fatty acid, and the absorption, osteoclast synthesis, prostaglandin by adjusting calcium are closed
The growth metabolism that bone is influenced at equal inhibits arthritis reaction, relieves pain.
Turmeric is turmeric zingiberaceous plant, and main active is curcumin, and curcumin has anti-infective, anti-oxidant and anti-
Inflammation effect etc..
Piperine by inhibiting the expression of the inflammatory factors such as Serum TNF-α, IL-1 β, IL-6 during arthritis, thus
Play the role of inhibiting osteoarthritis.
Bromelain and papain are extracted from pineapple and pawpaw respectively to be obtained, and bromelain has anti-inflammatory,
Inhibit immune cell responses, promotes the effect of absorption of nutrient ingredients；Papain has extremely strong capacity of decomposition, can promote fibre
The hydrolysis of fibrillarin eliminates the fibrin as caused by the reasons such as inflammation or wound, makes inflammatory resolution, plays anti-inflammatory, elimination
The effect of oedema.
Antiphlogistic can block the cell factors such as TNF-α, IL-1, IL-6 and related inflammation signal path, can also pass through
The generation of inhibitory activity oxygen removes free radical and peroxide and plays antioxidation；Antioncotic being capable of fiber in intensive aspect
The hydrolysis of albumen, fibrin and dissolution of blood clot by obstruction in tissue cause so as to improve the local circulation of body fluid
The elimination of inflammation and oedema can reach repairing articular cartilage, diminish inflammation and react, eliminate joint after acting synergistically with each raw material
Swelling, strong ligament, the effect for increasing muscle.
The ginseng is the one of which in ginseng stem and leave general saponin, ginsenoside and ginseng pulverate.
The just milkiness albumen includes the ingredient of following weight backup ratio: sheep milk powder 40%, milk powder 35%, collagen protein powder
20%, α-lactalbumin 1%, first milk basic protein 1%, magnesium stearate 1.5% and Se-enriched yeast 1.5%.
The astaxanthin is haematococcus pluvialis extract.
The preparation method of the raw haematococcus astaxanthin pressed candy the following steps are included:
1. stock: weighing the following raw material: astaxanthin 19.5%, isomalt 20%, colostrum alkalinity egg by mass percentage
White 10%, ginseng 1.5%, microcrystalline cellulose 47%, vitamin D 0.95% and vitamin C 0.95%, anti-inflammatory agent 0.05% and antioncotic
0.05%；
2. mixing: by astaxanthin, isomalt, first milk basic protein, ginseng, microcrystalline cellulose, vitamin D, vitamin C,
Anti-inflammatory agent and antioncotic are placed in batch mixer, and 30min is mixed under the revolving speed of 1500r/min and obtains mixture；
3. sterilizing: mixture is placed in sterilizer, 120 DEG C at a temperature of sterilize 6s；
4. tabletting: by the mixture input tablet press machine after sterilizing, tabletting is carried out under the pressure of 100KN, obtains pressed candy；
5. packaging: the pressed candy after tabletting is subjected to quality testing, and carries out disinfection by ultraviolet light, packaging, can be prepared by finished product,
The quality of pressed candy is 0.5g.
Antioxidant astaxanthin and people are participated in isomalt, first milk basic protein crystallite fibre by the present embodiment 1~4
Dimension element, vitamin D and vitamin C combine according to a certain percentage, play its complementary and synergistic effect, and antioxidant effect is preferable, and
The effect of many kinds of substance can be played simultaneously, interior free yl can be removed, it is anti-inflammatory, anti-inflammatory, joint flexibility ratio is improved, makes action more
Add smooth, and aerobic metabolism can be strengthened, reduce myalgia, improve endurance；Muscle damage is reduced, recovery time is shortened；Promote
Fat combustion obtains higher energy grade；Function of joint, enhancing immunity of organisms after can also maintaining strenuous exercise, not only have
Have that product is in good taste, quality is stable, full of nutrition, food therapy effect is significant, easy to carry, preparation method is simple, is easy to batch production
The advantages of production, and further enrich the food products market of Astaxanthin In Haematococcus Pluvialis, be very suitable to arthritic or
The crowd for relieving fatigue movement drinks.
In order to examine the present invention do not grudge product to maintenance joint and connective tissue curative effect, carried out following test:
One, object is drunk
Choosing the age has arthritis or knee joint, ankle-joint, hip joint in frequent running either various sport peoples
Pain is while approximate 100 experimenters of pain degree；It is randomly divided into 4 groups, every group of 20 people, respectively first group, second group,
Three groups and the 4th group；
Two, instructions of taking
The product of first group of oral embodiment 1, the product of second group of oral embodiment 2, third group take orally the product of embodiment 3,
The product of 4th group of oral embodiment 4, it is 2 oral every time, 3 times a day (morning, noon, each at night primary), take 10 days, 10
Pain test is carried out after it, during taking, is stopped movement, the high load capacities activity such as work, but rest without having a holiday, is carried out as usual
The life activities such as common work and study.
Three, the record of test result is as follows:
In the first set: having the disappearance of 15 people's feeling of pains, there are 9 people to have slight sense pain, there is 1 people's pain to have alleviation；
In the second set: having the disappearance of 20 people's feeling of pains, there are 5 people to have slight sense pain；
In third group: 25 whole people's feeling of pains disappear；
In the first set: having the disappearance of 21 people's feeling of pains, there are 4 people to have slight sense pain；
There is the pain symptom of 81 people to completely disappear from above-mentioned can be seen that in 100 experimenters from test result, there is 18
People only has slight feeling of pain, has the feeling of pain of 1 people to be alleviated, and the effective percentage for weakening or curing has reached 99% or more, in fact
Test subsequent tracking in 3 months, persistently taken in object of fully recovering 60 resume training after without sending out again.
Above-mentioned experiment confirms that this product is uncomfortable to solution joint is facilitated, balanced nutritious, reaches repairing articular cartilage, eliminates inflammation
Arthroncus, strong ligament, the effect for increasing muscle are eliminated in disease reaction, are taken energy Saving cortilage tissue for a long time, are inhibited inflammation,
Promote the reparation of joint injury.
Claims (9)
1. it is a kind of safeguard joint and connective tissue health Astaxanthin In Haematococcus Pluvialis pressed candy, it is characterised in that: including with
The raw material of lower mass percentage content: astaxanthin 15~30%, isomalt 5~20%, first milk basic protein 10~20%,
Ginseng 0.5~2%, microcrystalline cellulose 30~47%, vitamin D 0.5~1% and vitamin C 0.5~1%.
2. a kind of Astaxanthin In Haematococcus Pluvialis pressed candy for safeguarding joint and connective tissue health according to claim 1
Fruit, it is characterised in that: further include 0.5~1% auxiliary material in the raw material.
3. a kind of Astaxanthin In Haematococcus Pluvialis pressed candy for safeguarding joint and connective tissue health according to claim 2
Fruit, it is characterised in that: the auxiliary material includes the ingredient of following parts by weight: 1~20 part of inulin, 1~10 part of seabuckthorn fruit powder and blueberry
1~10 part of dry powder.
4. a kind of Astaxanthin In Haematococcus Pluvialis pressed candy for safeguarding joint and connective tissue health according to claim 1
Fruit, it is characterised in that: further include 0.01~0.05% anti-inflammatory agent and 0.01~0.05% antioncotic in the raw material.
5. a kind of Astaxanthin In Haematococcus Pluvialis pressed candy for safeguarding joint and connective tissue health according to claim 4
Fruit, it is characterised in that: the anti-inflammatory agent includes one of and two or more in fish oil, olive oil, curcumin and piperine
Mixture；The antioncotic includes one of which or two kinds of mixture in bromelain and papain.
6. a kind of Astaxanthin In Haematococcus Pluvialis pressed candy for safeguarding joint and connective tissue health according to claim 1
Fruit, it is characterised in that: the ginseng is the one of which in ginseng stem and leave general saponin, ginsenoside and ginseng pulverate.
7. a kind of Astaxanthin In Haematococcus Pluvialis pressed candy for safeguarding joint and connective tissue health according to claim 1
Fruit, it is characterised in that: the just milkiness albumen includes the ingredient of following weight backup ratio: sheep milk powder 20~40%, milk powder 20~
40%, collagen protein powder 10~30%, α-lactalbumin 1~5%, first milk basic protein 1~5%, magnesium stearate 0.5~2% and selenium-rich
Yeast 1~5%.
8. a kind of Astaxanthin In Haematococcus Pluvialis pressed candy for safeguarding joint and connective tissue health according to claim 1
Fruit, it is characterised in that: the astaxanthin is haematococcus pluvialis extract.
9. a kind of Astaxanthin In Haematococcus Pluvialis pressed candy for safeguarding joint and connective tissue health according to claim 1
Fruit, it is characterised in that: the preparation method of raw haematococcus astaxanthin pressed candy the following steps are included:
1. stock: weighing the following raw material: astaxanthin 15~30%, isomalt 5~20%, colostrum alkali by mass percentage
Property protein 10~20%, ginseng 0.5~2%, microcrystalline cellulose 30~47%, vitamin D 0.5~1% and vitamin C 0.5~1%；
2. mixing: by astaxanthin, isomalt, first milk basic protein, ginseng, microcrystalline cellulose, vitamin D and vitamin C
It is placed in batch mixer, 20~30min is mixed under the revolving speed of 1000~1500r/min and obtains mixture；
3. sterilizing: mixture is placed in sterilizer, 100~120 DEG C at a temperature of sterilize 5~6s；
4. tabletting: by the mixture input tablet press machine after sterilizing, tabletting is carried out under the pressure of 50~100KN, obtains tabletting
Candy；
5. packaging: the pressed candy after tabletting is subjected to quality testing, and carries out disinfection by ultraviolet light, packaging, can be prepared by finished product,
The quality of pressed candy is 0.5 ± 0.01g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910045882.6A CN109601680A (en) | 2019-01-17 | 2019-01-17 | A kind of maintenance joint and the Astaxanthin In Haematococcus Pluvialis pressed candy of connective tissue health and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910045882.6A CN109601680A (en) | 2019-01-17 | 2019-01-17 | A kind of maintenance joint and the Astaxanthin In Haematococcus Pluvialis pressed candy of connective tissue health and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109601680A true CN109601680A (en) | 2019-04-12 |
Family
ID=66019812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910045882.6A Pending CN109601680A (en) | 2019-01-17 | 2019-01-17 | A kind of maintenance joint and the Astaxanthin In Haematococcus Pluvialis pressed candy of connective tissue health and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109601680A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110236147A (en) * | 2019-05-08 | 2019-09-17 | 深圳市淳睿科技发展有限公司 | Halth-care composition, preparation method and its application |
| CN113925166A (en) * | 2020-12-14 | 2022-01-14 | 常州市第二人民医院 | Astaxanthin composition and preparation method thereof |
| CN114431328A (en) * | 2022-02-11 | 2022-05-06 | 青岛海智源生命科技有限公司 | Composite tablet candy capable of improving symptoms of female dysmenorrhea |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130287756A1 (en) * | 2009-07-23 | 2013-10-31 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to alleviate joint pain |
| CN104770636A (en) * | 2015-03-03 | 2015-07-15 | 青岛森淼实业有限公司 | Nutritional supplement containing astaxanthin and prebiotics and press candy prepared from same |
| CN106689618A (en) * | 2016-11-21 | 2017-05-24 | 云南爱尔康生物技术有限公司 | Astaxanthin tabletting candy preparation method |
| CN107259046A (en) * | 2017-06-07 | 2017-10-20 | 陕西必康制药集团控股有限公司 | Haematococcus pluvialis pressed candy with anti-oxidation function and preparation method thereof |
| CN108741099A (en) * | 2018-06-11 | 2018-11-06 | 广州尚天诚品生物科技有限公司 | One kind contributing to comfortable alimentation composition in joint and its preparation method and application |
-
2019
- 2019-01-17 CN CN201910045882.6A patent/CN109601680A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130287756A1 (en) * | 2009-07-23 | 2013-10-31 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to alleviate joint pain |
| CN104770636A (en) * | 2015-03-03 | 2015-07-15 | 青岛森淼实业有限公司 | Nutritional supplement containing astaxanthin and prebiotics and press candy prepared from same |
| CN106689618A (en) * | 2016-11-21 | 2017-05-24 | 云南爱尔康生物技术有限公司 | Astaxanthin tabletting candy preparation method |
| CN107259046A (en) * | 2017-06-07 | 2017-10-20 | 陕西必康制药集团控股有限公司 | Haematococcus pluvialis pressed candy with anti-oxidation function and preparation method thereof |
| CN108741099A (en) * | 2018-06-11 | 2018-11-06 | 广州尚天诚品生物科技有限公司 | One kind contributing to comfortable alimentation composition in joint and its preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| 张雅利，等: "《营养与健康》", 31 December 2018, 西安交通大学出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110236147A (en) * | 2019-05-08 | 2019-09-17 | 深圳市淳睿科技发展有限公司 | Halth-care composition, preparation method and its application |
| CN113925166A (en) * | 2020-12-14 | 2022-01-14 | 常州市第二人民医院 | Astaxanthin composition and preparation method thereof |
| CN114431328A (en) * | 2022-02-11 | 2022-05-06 | 青岛海智源生命科技有限公司 | Composite tablet candy capable of improving symptoms of female dysmenorrhea |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109123643A (en) | A kind of preparation method of cereal generation meal ball | |
| CN109601680A (en) | A kind of maintenance joint and the Astaxanthin In Haematococcus Pluvialis pressed candy of connective tissue health and preparation method thereof | |
| CN108719984B (en) | Meal replacement nutrition bar for gout population and preparation method thereof | |
| Kumar et al. | Green blood therapy of wheat grass-Nature’s finest medicine’-A literature review | |
| CN105124347A (en) | Moringa oleifera blood-glucose-reducing composition and preparation method thereof | |
| CN110583780A (en) | A solid beverage for preventing and reducing hypertension and hyperuricemia | |
| CN115736142A (en) | Formula and preparation process of prebiotics prune fiber fruit drink | |
| CN106418501A (en) | Healthcare food with weight reducing function | |
| CN102090563A (en) | Relaxing and sleeping health-care food and preparation method thereof | |
| CN105146609A (en) | Lipid-lowering intestine-moistening vinegar drink and preparation method thereof | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN111184214A (en) | Enzyme collagen coarse cereal, fruit and vegetable instant meal replacement porridge and making method thereof | |
| CN103238889A (en) | Anti-fatigue apple vinegar health beverage and preparation method thereof | |
| CN105707378A (en) | Black-highland barley coffee with effect of slimming | |
| CN101077144A (en) | Fruity noodle | |
| CN106174286A (en) | Senior gold Chinese-wolfberry nutritive fruit jam | |
| KR20080090808A (en) | Composition of healthy food for a skin | |
| CA2607267A1 (en) | Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage | |
| KR100977849B1 (en) | Composition for Juice of Fruits and Vegetables Containing Kimchi's Lactic Acid Bacterias | |
| CN1943695A (en) | A tortoise preparation and its production technology | |
| CN115553406A (en) | Weight-reducing composition beverage for inhibiting absorption of fat and sugar substances and preparation method thereof | |
| CN114617267A (en) | Reinforced composite bone peptide and preparation method and application thereof | |
| CN101224005B (en) | Nutrient tablet possessing whole nutrient supplementing efficacy and producing method thereof | |
| KR102480311B1 (en) | The manufacturing method of making healthcare food composition for costitutional group | |
| CN100506085C (en) | Brown sugar health product capable of raising immunity of puerpera |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190412 |
|
| RJ01 | Rejection of invention patent application after publication |